Ozanimod vs Fingolimod for Multiple Sclerosis
Trial Summary
What is the purpose of this trial?
The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators for more details.
What data supports the effectiveness of the drug Ozanimod compared to Fingolimod for multiple sclerosis?
What is the safety profile of Ozanimod and Fingolimod for multiple sclerosis?
How does the drug ozanimod differ from fingolimod for multiple sclerosis?
Research Team
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Eligibility Criteria
This trial is for children and adolescents with Relapsing Remitting Multiple Sclerosis (RRMS). Specific eligibility criteria are not provided, but typically participants must meet certain health standards and may be required to have a confirmed diagnosis of RRMS.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either ozanimod or fingolimod to evaluate effectiveness, safety, and tolerability
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Fingolimod
- Ozanimod
Fingolimod is already approved in European Union, United States, Canada for the following indications:
- Relapsing forms of multiple sclerosis
- Relapsing forms of multiple sclerosis
- Relapsing forms of multiple sclerosis
Find a Clinic Near You
Who Is Running the Clinical Trial?
Celgene
Lead Sponsor
Jay Backstrom
Celgene
Chief Medical Officer since 2016
MD
Mark Alles
Celgene
Chief Executive Officer since 2016
Bachelor's degree from Lock Haven University of Pennsylvania